Rankings
▼
Calendar
DYN
Dyne Therapeutics, Inc.
$3B
Q4 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$5M
Net Income
-$5M
EPS (Diluted)
$-0.42
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$5M
Stock-Based Comp.
$14,000
Balance Sheet
Total Assets
$16M
Total Liabilities
$2M
Stockholders' Equity
$14M
Cash & Equivalents
$15M
← FY 2019
All Quarters
Q1 2020 →
DYN Q4 2019 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
